Skip to main content

Advertisement

Table 2 Vitamin D receptor expression in relation to breast cancer mortality

From: Vitamin D receptor expression in invasive breast tumors and breast cancer survival

 Total (n)Person-yearsDead from breast cancerBreast cancer mortality/100 000HRaHRbHRc,#HRc,*
Nuclear VDR fraction0–10% (neg)12513103425951.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
11–100% (pos)55364147712000.46 (0.31–0.69)0.42 (0.28–0.63)0.61 (0.35–1.05)0.56 (0.34–0.91)
Nuclear VDR fraction0–10%12513103425951.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
11–50%43750556112060.47 (0.31–0.71)0.41 (0.27–0.63)0.57 (0.32–1.01)0.54 (0.32–0.89)
51–100%11613591611770.46 (0.25–0.83)0.44 (0.24–0.79)0.74 (0.35–1.55)0.66 (0.34–1.28)
Cytoplasmic VDR score0–6 (neg)576091727911.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
7–12 (pos)62271379413170.47 (0.28–0.79)0.44 (0.26–0.74)0.88 (0.39–1.97)0.59 (0.30–1.16)
Cytoplasmic VDR score0–6576091727911.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
7–915217122514600.52 (0.28–0.96)0.50 (0.27–0.92)1.01 (0.43–2.40)0.58 (0.27–1.24)
10–1247054256912720.45 (0.27–0.77)0.42 (0.25–0.72)0.81 (0.36–1.86)0.59 (0.30–1.18)
  1. aCrude analysis
  2. bAdjusted for age at and season of diagnosis
  3. cAdjusted for same factors as b but also for size of tumor, lymph node status, histological type, and molecular subtypes
  4. #Complete case analysis: analysis including only cases with complete information on all covariates
  5. *Multiple imputation performed to include individuals with missing data on covariates in analysis